| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
MC-Val-Ala-OH does not have a direct pharmacological target, as it is a linker molecule used in the synthesis of ADCs. Its function is to connect an antibody to a cytotoxic payload in ADC constructs. The valine-alanine peptide sequence is designed to be cleaved by specific proteases, such as cathepsin B, which are overexpressed in tumor cells. This protease-sensitive cleavage enables the selective release of the cytotoxic payload inside target cells, minimizing off-target toxicity.
|
|---|---|
| ln Vitro |
ADC cytotoxins are connected to antibodies through an ADC connector to form ADCs [1].
MC-Val-Ala-OH does not possess intrinsic biological activity as it is a linker molecule rather than a pharmacologically active compound. Its in vitro utility lies in its use as a chemical building block for the synthesis of ADCs. The compound's peptide sequence allows for protease-sensitive cleavage, which is essential for the targeted release of the payload in cancer cells. In vitro studies typically involve testing the stability of the linker in plasma and its cleavage efficiency in the presence of cathepsin B. |
| ln Vivo |
In vivo activity is not applicable to MC-Val-Ala-OH itself, as it is a linker molecule used in the synthesis of ADCs rather than a pharmacologically active compound. The in vivo activity would be associated with the final ADC molecules that incorporate this linker, not with the linker itself. MC-Val-Ala-OH is used exclusively as a chemical building block in research settings to construct ADC molecules that can deliver cytotoxic payloads to target cells.
|
| Enzyme Assay |
In vitro enzyme/receptor binding experiments are not applicable to MC-Val-Ala-OH, as it is a linker molecule rather than a biologically active compound. The compound is used as a chemical building block in bioconjugation reactions. Its characterization involves chemical analysis methods such as NMR spectroscopy, HPLC, and mass spectrometry to confirm its structure and purity. Researchers use these analytical techniques to verify the identity and quality of the compound before using it in the synthesis of ADCs.
|
| Cell Assay |
In vitro cellular experiments are not performed with MC-Val-Ala-OH itself, as it is a linker molecule used in bioconjugation rather than a biologically active compound. The compound is used exclusively as a building block for the synthesis of ADCs. Researchers handling MC-Val-Ala-OH follow standard chemical synthesis protocols, including the use of appropriate personal protective equipment and working in a fume hood. The compound is stored under conditions that maintain its chemical stability.
|
| Animal Protocol |
In vivo animal experiments are not applicable to MC-Val-Ala-OH itself, as it is a linker molecule used in the synthesis of ADCs rather than a pharmacologically active compound. The compound is not administered to animals, and its biological effects have not been studied in vivo. Any animal studies would be conducted with the final ADC molecules that are synthesized using this linker, not with the linker itself.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties are not applicable to MC-Val-Ala-OH itself, as it is a linker molecule used in bioconjugation rather than a pharmacologically active drug candidate. The compound is not intended for administration to animals or humans, and its absorption, distribution, metabolism, and excretion have not been studied. MC-Val-Ala-OH is used exclusively as a building block for the synthesis of ADCs. Its physicochemical properties, such as molecular weight (381.42) and solubility (DMSO 100 mg/mL), are relevant to its handling in chemical reactions.
|
| Toxicity/Toxicokinetics |
Toxicological data for MC-Val-Ala-OH are limited, as the compound is a chemical linker rather than a drug candidate. Standard safety precautions for handling organic chemicals apply, including the use of personal protective equipment and working in a well-ventilated area. The compound is not intended for human consumption, and its toxicity profile has not been extensively characterized. Researchers handling MC-Val-Ala-OH should refer to the material safety data sheet (MSDS) for specific hazard information.
|
| References | |
| Additional Infomation |
MC-Val-Ala-OH is a research chemical that has not entered clinical trials or received regulatory approval for therapeutic use. It is a cleavable ADC linker used in the synthesis of antibody-drug conjugates, a class of targeted therapeutics that deliver cytotoxic payloads to cancer cells. The compound's valine-alanine peptide sequence enables protease-sensitive payload release, making it valuable for ADC development. Its cleavable nature and compatibility with various payloads make it a useful tool for targeted cancer therapy research.
|
| Molecular Formula |
C₁₈H₂₇N₃O₆
|
|---|---|
| Molecular Weight |
381.42
|
| Exact Mass |
381.19
|
| CAS # |
1342211-31-7
|
| PubChem CID |
67452206
|
| Appearance |
White to off-white solid powder
|
| Density |
1.232±0.06 g/cm3(Predicted)
|
| Boiling Point |
695.4±50.0 °C(Predicted)
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
27
|
| Complexity |
611
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C[C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)CCCCCN1C(=O)C=CC1=O
|
| Synonyms |
MCValAlaOH; MC Val Ala OH
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~655.45 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.45 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.45 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (5.45 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6218 mL | 13.1089 mL | 26.2178 mL | |
| 5 mM | 0.5244 mL | 2.6218 mL | 5.2436 mL | |
| 10 mM | 0.2622 mL | 1.3109 mL | 2.6218 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
